Disc Medicine, Inc. (IRON) Stock Analysis
Healthcare · Biotechnology · NasdaqGM
Disc Medicine, Inc. (IRON) posted $0 in revenue for fiscal 2025, with a net loss of $212.18M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Disc Medicine, Inc.
Disc Medicine, Inc. has grown revenue from $0 to $0 over the last 6 fiscal years.
It carries about $29.16M of total debt.
The one thing worth a second look in the filings is debt with negative operating cash flow.
Synthesised from Disc Medicine, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Disc Medicine, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-40.84M | $-35.97M | $-46.83M | $-76.43M | $-109.36M | $-212.18M |
| Net margin | — | — | — | — | — | — |
Source: Disc Medicine, Inc. SEC filings (10-K).
Disc Medicine, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Debt with negative operating cash flowCarries $29.2M of debt while last year's operating cash flow was negative ($-180.4M).
Explore 6 years of Disc Medicine, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IRON in your portfolio →
Disc Medicine, Inc. financial history by metric
About Disc Medicine, Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Disc Medicine, Inc. — frequently asked questions
What is Disc Medicine, Inc.'s revenue?
Disc Medicine, Inc. (IRON) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Disc Medicine, Inc. profitable?
No — IRON reported a net loss of $-212.18M in fiscal 2025.
What is IRON's P/E ratio?
Disc Medicine, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Disc Medicine, Inc. have?
As of fiscal year 2025, IRON carried roughly $29.16M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Disc Medicine, Inc.'s market cap?
Disc Medicine, Inc. (IRON) has a market capitalization of about $2.61B, based on the latest data in our nightly-refreshed cache.
When does Disc Medicine, Inc.'s fiscal year end?
IRON's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Disc Medicine, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.